Startup profile · funding coverage
Amber funding, valuation and investors
RNA-based multi-kilobase gene editing platform for diseases with high allelic diversity.
Keep track of Amber
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Seed
$26M · August 2023
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$26M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
seed · San Francisco, California
Investors in latest funding
Other: Andreessen Horowitz
Overview
Amber Bio (amber.bio) develops Cas-based RNA writing tools that enable kilobase-scale edits on RNA strands. Co-founders Jacob Borrajo and Basem Al-Shayeb (Broad Institute and UC Berkeley gene-editing backgrounds) aim to treat genetically heterogeneous diseases with a single therapeutic rather than one program per mutation.
Why Amber is interesting
Amber Bio edits RNA instead of DNA for reversible, multi-kilobase corrections — Broad/Berkeley founders targeting mutation-diverse diseases where one drug can cover many variants.
Product & use cases
Amber Bio (amber.bio) develops Cas-based RNA writing tools that enable kilobase-scale edits on RNA strands.
- Primary product use case per company site
- Enterprise or consumer deployment
Key facts
- Seed (Aug 2023): $26M co-led by Playground Global and a16z Bio + Health; ARCH Venture Partners, Eli Lilly, RDF, Hummingbird, Pillar VC participated (Business Wire)
- Platform: multi-kilobase RNA editing for allelic-diverse genetic diseases (Amber Bio site)
- Co-investors not in VCT directory: Playground Global, Eli Lilly, RDF, Hummingbird Ventures, Pillar VC
Funding history (newest first)
Unknown
Source: Source reference not linked
Investors in our directory
Funds linked from Amber's profile — open a fund page for stage focus and related deal articles.
Competitive landscape
Edge: Amber Bio edits RNA instead of DNA for reversible, multi-kilobase corrections — Broad/Berkeley founders targeting mutation-diverse diseases where one drug can cover many variants.
Amber competes in biotech-life-sciences. Incumbents have distribution; startup edge depends on product depth and buyer references. See competitors for specific tradeoffs — no invented market share claims.
-
Veeva incumbent
Life sciences cloud incumbent.
-
Dotmatics adjacent
R&D informatics.
Notable stories
- Seed (Aug 2023): $26M co-led by Playground Global and a16z Bio + Health; ARCH Venture Partners, Eli Lilly, RDF, Hummingbird, Pillar VC participated (Business Wire)
- Platform: multi-kilobase RNA editing for allelic-diverse genetic diseases (Amber Bio site)
Industries
Market / IPO context
Editorial / static context — not a live quote.
Related funding articles
Venture Capital Tracker pieces that cover Amber's financing or category context.
FAQs about Amber
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.